Back

Impact of mitral valvular and subvalvular abnormalities on response to mavacamten in obstructive hypertrophic cardiomyopathy

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Echocardiography in cardiomyopathy: from research to real-world practice Myocardial Disease ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Morgane Herry

Hospital Lariboisiere, Paris (France)

3 More presentations in this session

Presentation thumbnail
Echocardiographic assessment of right ventricular hypertrophy and right ventricular-pulmonary artery coupling in hypertrophic cardiomyopathy—implications for outcomes
Mrs A. Clement (Iasi, RO)
Abstract Slides Video
Presentation thumbnail
Incremental prognostic value of advanced echocardiographic over standard 2D assessment in a real-world clinical population
Doctor G. Benzoni (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac function evaluated with myocardial strain of the four cardiac chambers in adult patients with genetic familial hypercholesterolemia
Doctor L. Soulat-Dufour (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Echocardiography in cardiomyopathy: from research to real-world practice

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Echocardiographic evolution of symptomatic patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: experience of a portuguese terciary care center
20 May 2025
thumbnail
Congress Presentation
Real-world experience with mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy
30 August 2026
thumbnail
Congress Presentation
Baseline global longitudinal strain and mechanical dispersion predict ejection fraction decline during mavacamten therapy in obstructive hypertrophic cardiomyopathy
29 August 2026
thumbnail
Congress Presentation
Mavacamten shows benefits in patients with symptomatic obstructive hypertrophic cardiomyopathy with latent obstruction: global evidence from COLLIGO-HCM
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources